Recent oncology dealmaking trends provide insights on strategies for dealmaking in the current market.

Several recent billion-dollar merger and acquisition deals have expanded the range of services provided by leading molecular diagnostics companies.

Companies are investing in a range of pioneering strategies in the search for the next therapeutic advances for immuno-inflammatory diseases.

Many biotechs completed private financing rounds during Autumn which focused on immunotherapy development and more.

A next-generation diagnostic test developed by Haystack Oncology detects the presence of minimal residual disease in early-stage cancer patients after curative-intent surgery. By identifying residual disease—which Haystack achieves through accurately measuring circulating tumor DNA in blood—clinicians can make more-informed decisions to help their patients achieve better outcomes.

The Korea Drug Development Fund (KDDF), through its investment and support of the biopharma sector, translates cutting-edge science into patient benefits and market opportunities.

LR 09, a metabolic immune-checkpoint inhibitor that can initiate graft-versus-leukemia effect in relapsed allogeneic stem-cell transplant (SCT) patients, could become the new standard of care for leukemia.

Ellipses Pharma’s KOL-enabled cloud-based platform is crowdsourcing expert insight from oncologists worldwide to create tailored opportunities for developing drug candidates.

With a lead candidate harnessing antibody-driven cytotoxic mechanisms to drive tumor cell death, Byondis is developing a pipeline of candidates targeting oncology by combining its unrivaled expertise in linker-drug technology, antibody–drug conjugation, targeted cytotoxic therapy and the development of monoclonal antibodies.

New York- and Alabama-based IN8bio is leveraging gamma-delta (γδ) T cell biology to merge innate and adaptive immune capabilities against cancer.

Affivant Sciences is developing tetravalent, bispecific antibodies that can recruit multiple innate immune-cell types to attack a range of challenging cancers.

Strike Pharma has developed new affinity-based linkers for optimized delivery of tumor-specific immunogenic peptides to immune cells, creating more efficacious personalized immunotherapies with fewer side effects.

Eterna Therapeutics is using state-of-the-art messenger RNA (mRNA) technology to develop cell and gene therapies for cancer and a wide range of other indications.